^
    Back
    Association details:
    Biomarker:KIAA1549-BRAF fusion
    Cancer:Astrocytoma
    Drug:Koselugo (selumetinib) (MEK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    AZD6244 in Children With Low-Grade Gliomas

    Excerpt:
    ...- Stratum 1: Patients with progressive, recurrent or refractory pilocytic astrocytoma with pre-trial tumor material available and with a BRAF aberration i.e. BRAF (V600E) mutation and/or BRAF KIAA1549 fusion as determined by IHC and FISH, respectively. ...
    Trial ID:
    NCT01386450
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma

    Excerpt:
    ...Plasma drug concentrations and pharmacokinetic parameters (Phase I)`Stratum-specific progression-free survival distribution (PFS) (phase II)`Presence or absence of BRAF V600E mutations or BRAF KIAA1549 fusion (phase II)`Progression-free survival (retreatment study)...
    Trial ID:
    NCT01089101
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Lancet Oncol
    Title:

    Selumetinib in Children with BRAF-Aberrant or Neurofibromatosis type 1-Associated Recurrent, Refractory or Progressive Low-Grade Glioma: a Multi-Center Phase II Trial

    Excerpt:
    ...Stratum 1 included...pilocytic astrocytoma (PA) harboring either one of the two most common BRAF aberrations (KIAA1549-BRAF fusion or the BRAFV600E mutation)...On stratum 1, 9/25 (36%) patients achieved a partial response (PR)...Among the tumors with a KIAA1549-BRAF fusion, 7/18 (38.9%) had a PR...
    DOI:
    10.1016%2FS1470-2045(19)30277-3
    Trial ID:
    NCT01089101